利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.038 秒)

    Methods for inhibiting the production of HIV-1 retrovirus using monoclonal antibodies and Fv specific for CD2 antigen
    2.
    发明授权
    Methods for inhibiting the production of HIV-1 retrovirus using monoclonal antibodies and Fv specific for CD2 antigen 失效
    使用单克隆抗体和特异于CD2抗原的Fv抑制HIV-1逆转录病毒生产的方法

    公开(公告)号：US06384198B1

    公开(公告)日：2002-05-07

    申请号：US08443888

    申请日：1995-05-31

    申请人： Michael L Diegel ,  Peter S Linsley ,  Lisa K Gilliland ,  Patricia A Moran ,  Joyce M Zarling ,  Jeffrey A Ledbetter

    发明人： Michael L Diegel ,  Peter S Linsley ,  Lisa K Gilliland ,  Patricia A Moran ,  Joyce M Zarling ,  Jeffrey A Ledbetter

    IPC分类号： C07K1628

    CPC分类号： C07K16/2806 ,  A61K38/00 ,  A61K47/6849 ,  C07K16/00 ,  C07K2317/73 ,  C07K2319/30

    摘要： An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric nonclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional non-HIV-1-producing T cells in the patient.

    摘要翻译： 根据本发明的抗CD2单克隆抗体可以是：（1）通过表达克隆在重组大肠杆菌培养物ATCC No.69277中的构建体产生的嵌合非克隆抗体CD2 SFv-Ig; （2）具有与CD2 SFv-Ig相同的互补决定区的单克隆抗体; 或（3）与CD2 SFv-Ig竞争结合CD2抗原的单克隆抗体与CD2 SFv-Ig按摩尔计有效地至少约80％。 根据本发明的抗CD2单克隆抗体以及可以调节T淋巴细胞和单核细胞之间的相互作用的其它抗体可用于抑制HIV-1感染的HIV-1感染的T细胞在HIV-1中的产生 感染患者。 在另一种用途中，体外治疗的T细胞可以被再次输入艾滋病患者，以增加患者中产生功能性非HIV-1的T细胞的比例。

    Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
    4.
    发明授权
    Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity 失效
    用于调节淋巴细胞活性的抗体异源偶联物和双特异性抗体

    公开(公告)号：US6010902A

    公开(公告)日：2000-01-04

    申请号：US366401

    申请日：1994-12-29

    申请人： Jeffrey A. Ledbetter ,  Lisa K. Gilliland

    发明人： Jeffrey A. Ledbetter ,  Lisa K. Gilliland

    IPC分类号： C07K16/28 ,  C07K16/46 ,  C12P21/08 ,  C12N5/00 ,  C07K16/00 ,  C12N5/02

    CPC分类号： C07K16/2896 ,  C07K16/2806 ,  C07K16/2809 ,  C07K16/2812 ,  C07K16/2815 ,  C07K16/2818 ,  C07K16/289 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/73

    摘要： The present invention relates to novel antibody heteroconjugates and bispecific antibodies and methods and compositions and their use in the enhancement or inhibition of activation and function of T or B lymphocytes. The heteroconjugates are comprised of at least two antibody molecules cross-linked to each other, each molecule being reactive with a different lymphocyte antigen on the same cell. The invention also provides bispecific antibodies comprising a first binding region reactive with an antigen on a lymphocyte and a second binding region reactive with a different antigen on the lymphocyte. The heteroconjugates, bispecific antibodies, methods and compositions of this invention are therefore useful in the regulation of lymphocyte function, resulting in the improvement of cellular immune responses in various disease states.

    摘要翻译： 本发明涉及新型抗体异源偶联物和双特异性抗体及其方法和组合物及其在增强或抑制T淋巴细胞或B淋巴细胞活化和功能中的用途。 异源偶联物由至少两个彼此交联的抗体分子组成，每个分子与相同细胞上的不同淋巴细胞抗原反应。 本发明还提供双特异性抗体，其包含与淋巴细胞上的抗原反应的第一结合区域和与淋巴细胞上的不同抗原反应的第二结合区域。 因此，本发明的异源偶联物，双特异性抗体，方法和组合物可用于调节淋巴细胞功能，导致改善各种疾病状态下的细胞免疫应答。

    Antibody variants
    8.
    发明授权
    Antibody variants 有权
    抗体变体

    公开(公告)号：US08440190B2

    公开(公告)日：2013-05-14

    申请号：US11180631

    申请日：2005-07-14

    申请人： Herman Waldmann ,  Lisa K Gilliland ,  Masahide Tone ,  Mark R Frewin ,  Louise Walsh

    发明人： Herman Waldmann ,  Lisa K Gilliland ,  Masahide Tone ,  Mark R Frewin ,  Louise Walsh

    IPC分类号： A61K39/00

    CPC分类号： C07K16/465 ,  A61K38/00 ,  C07K16/2893 ,  C07K2317/24 ,  C07K2319/00

    摘要： This invention relates to an antibody which is modified version of a therapeutic antibody with affinity for a cell-surface antigen, the antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable of inducing immunological tolerance to the therapeutic antibody. The invention further relates to a method of inducing immunological tolerance to a therapeutic antibody, comprising administering to a patient an antibody which is a modified version of the therapeutic antibody and which has reduced affinity for the antigen as compared with the therapeutic antibody.

    摘要翻译： 本发明涉及作为对抗体分子的修饰或修饰的结果与治疗性抗体相比具有降低的对抗原亲和性的抗体的抗体，该抗体是对细胞表面抗原具有亲和力的治疗性抗体的修饰形式，其中 抗体能够诱导对治疗性抗体的免疫耐受性。 本发明还涉及一种诱导对治疗性抗体的免疫耐受性的方法，其包括与治疗性抗体相比，向患者施用作为治疗性抗体的修饰形式的抗体，并且其对抗原的亲和力降低。

    Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
    10.
    发明授权
    Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy 失效
    对人类GP39的不同表位有特异性的单克隆抗体及其在诊断和治疗中的应用

    公开(公告)号：US5876950A

    公开(公告)日：1999-03-02

    申请号：US379057

    申请日：1995-01-26

    申请人： Anthony W. Siadak ,  Diane L. Hollenbaugh ,  Lisa K. Gilliland ,  Marcia L. Gordon ,  Jurgen Bajorath ,  Alejandro A. Aruffo

    发明人： Anthony W. Siadak ,  Diane L. Hollenbaugh ,  Lisa K. Gilliland ,  Marcia L. Gordon ,  Jurgen Bajorath ,  Alejandro A. Aruffo

    IPC分类号： G01N33/53 ,  A61K38/00 ,  A61K47/48 ,  A61P37/06 ,  C07K14/705 ,  C07K16/28 ,  C12N5/10 ,  C12N15/09 ,  C12P21/08 ,  G01N33/577 ,  A61K39/395

    CPC分类号： C07K14/70575 ,  C07K16/2875 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2319/00

    摘要： The present invention provides monoclonal antibodies, antigen binding fragment and recombinant binding proteins specific for human gp39. These antibodies are specific for at least eight different epitopes on gp39. Hybridomas secreting specific antibodies which bind to these epitopes are also provided. Further, the present invention discloses the amino acid sequence of immunoglobulin light and heavy chain variable regions which bind to epitopes of gp39 and provide sFv and humanized antibodies which bind gp39. Also, provided are pharmaceutical compositions comprising the monoclonal antibodies, antigen binding fragments and recombinant binding proteins which bind gp39 and methods for using these compositions in diagnosing disease states, inhibiting B cell activation and for treating immunological disorders, such as autoimmune diseases, allergic responses, organ rejection and graft-versus-host disease. Antibodies of the present invention can also be used to image cells which express gp39 on their surface, such as tumor cells (e.g., lymphoma) and to target therapeutic agents to target cells.

    摘要翻译： 本发明提供了对人gp39特异的单克隆抗体，抗原结合片段和重组结合蛋白。 这些抗体对gp39上至少八个不同的表位是特异性的。 还提供了分泌结合这些表位的特异性抗体的杂交瘤。 此外，本发明公开了结合gp39的表位的免疫球蛋白轻链和重链可变区的氨基酸序列，并提供与gp39结合的sFv和人源化抗体。 此外，提供了包含单克隆抗体，抗原结合片段和结合gp39的重组结合蛋白的药物组合物，以及使用这些组合物诊断疾病状态，抑制B细胞活化和治疗免疫疾病如自身免疫性疾病，过敏反应的方法， 器官排斥和移植物抗宿主病。 本发明的抗体也可以用于在其表面上表达gp39的细胞（例如肿瘤细胞（例如淋巴瘤））成像，并将靶向治疗剂靶向靶细胞。